Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

INTRODUCTION: Pegloticase, a PEGylated recombinant porcine uricase, is approved for treating refractory gout at a dose of 8 mg intravenous (IV) every 2 weeks. However, during phase 1 testing, pharmacokinetics supported less frequent dosing. Also, single doses of pegloticase unexpectedly induced anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hershfield, Michael S, Ganson, Nancy J, Kelly, Susan J, Scarlett, Edna L, Jaggers, Denise A, Sundy, John S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060462/
https://www.ncbi.nlm.nih.gov/pubmed/24602182
http://dx.doi.org/10.1186/ar4500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060462/
https://www.ncbi.nlm.nih.gov/pubmed/24602182
http://dx.doi.org/10.1186/ar4500

Ejemplares similares